DRX9000 Spinal Decompression

[Here’s another press release from Axiom Worldwide. A special report supported by Axiom Worldwide on treating chronic lower back pain.]

TAMPA, Fla.–(BUSINESS WIRE)–In most industrialized countries, chronic low back pain is recognized as a widespread condition. However, a Special Report supported through a grant from Axiom Worldwide is now featured in the January issue of Pain Medicine News. The Special Report was first featured in the December 2007 issue of Anesthesiology News and was then presented on-line at: www.painmedicinenews.com in early January. The article has since become the most read article on this website. The Special Report highlights exciting research on a medical device that offers patients a non-surgical treatment option in treating chronic low back pain. The device is called the DRX9000™ and is manufactured by Axiom Worldwide of Tampa, FL. The authors of this Special Report are from the prestigious institutions of Duke University School of Medicine, Mayo Clinic, and Johns Hopkins University School of Medicine. They conclude their Special Report by stating, “The DRX9000™ computerized nonsurgical spinal decompression systems were designed to provide maximum patient benefits with the use of a noninvasive approach that may help minimize health care resources and offer a potentially optimal therapeutic approach to the treatment of LBP (low back pain).”

Axiom Worldwide manufactures and distributes its flagship products, the DRX9000 True Non-surgical Spinal Decompression System™, DRX9000C™, and DRX9500™ in medical markets around the globe. Axiom also manufactures a digital electroceutical device, the EPS8000™, for use in relieving pain and for use in muscular rehabilitation. Axiom prides itself on providing safe, non-surgical alternatives that patients should consider prior to undergoing surgery. For additional information or to receive a copy of the Special Report featured in Pain Medicine News please visit: www.AxiomWorldwide.com. To schedule an interview please contact: Gary Dixon, VP Sales and Marketing at: telephone: 001-813-249-6444 or email: gdixon@axiomworldwide.com.

Contact:
Axiom Worldwide, Tampa
Gary Dixon, 813-249-6444

[From Businesswire.com: In Las Vegas on February 7-9, 2008 Dr. John Leslie of The Mayo Clinic and others will be presenting the clinical results of a pilot study to examine the effectiveness and safety of the DRX9000 for treating chronic lower back pain.]

The clinical results of an IRB-approved prospective, multi-center phase II, non-randomized pilot study utilizing the DRX9000™ will be presented by two of its authors at the Parker Seminars Las Vegas February 7 – 9, 2008. The study, authored by Dr. John Leslie of The Mayo Clinic and others, was designed to evaluate the effectiveness and safety of the DRX9000 in the treatment of chronic lower back pain. Patients enrolled in the study had suffered an overall average of ten years of chronic back pain. After two weeks of treatment on the DRX9000 there was an average 50% reduction in pain scores and upon completion of the entire six week protocol an amazing success rate of 88.9% was documented. The investigators also noted an improvement in Oswestry Disability score.

A second study will also be presented in Las Vegas. This study titled, “Treatment of 94 Outpatients With Chronic Discogenic Low Back Pain with the DRX9000: A Retrospective Chart Review,” reports that patients with a mean pain duration of 535 weeks reported a mean verbal numerical pain intensity rating equal to 6.05 on a 0 to 10 scale prior to treatment with the DRX9000. This decreased to a statistically and clinically significant mean rating of 0.89 after the last treatment on the DRX9000. Patients also reported a decrease in analgesic use and improvement in activities of daily living. In addition, the authors were able to follow-up at a mean 31 weeks with 29 patients and reveal mean values of 83% improvement in back pain and satisfaction of 8.55 on a 10-point scale. None of these patients reported requiring surgery. The authors also acknowledge that there are other spinal decompression systems available commercially. However, they suggest that the design difference between these devices, “…may lead to differing physical responses to therapy, so studies of one type of apparatus should not readily be applied across all machines.” The study will be released in print in the March 2008 issue of Pain Practice. Copies of both poster presentations will be available.

Non-treatment or control groups were not included making efficacy outcome versus placebo or spontaneous recovery difficult to determine. Randomized double-blinded or comparative long-term outcome trials are needed to further prove the efficacy of non-surgical spinal decompression systems such as the DRX9000™ for the routine treatment of chronic LBP.

Axiom Worldwide manufactures and distributes its flagship products, the DRX9000 True Non-surgical Spinal Decompression System™, DRX9000C™, and DRX9500™ in medical markets around the globe. Axiom also manufactures a digital electroceutical device, the EPS8000™, for use in relieving pain and for use in muscular rehabilitation. Axiom prides itself on providing safe, non-surgical alternatives that patients should consider prior to undergoing surgery.

For additional information or to receive a copy of the data presented at Parker Seminars Las Vegas please visit: www.AxiomWorldwide.com. To schedule an interview please contact: Gary Dixon, VP Sales and Marketing at: telephone: 001-813-249-6444 or email: gdixon@axiomworldwide.com.